公开(公告)号：US20200382599A1

公开(公告)日：2020-12-03

申请号：US16880457

申请日：2020-05-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Andrzej Knafel ,  Thomas Weingartner ,  Benno Christian Trautmann ,  Daniel Howorth ,  Hartmut Mastall

IPC: H04L29/08 ,  H04L12/66 ,  H04L12/24 ,  G06F8/65

Abstract: A hospital or laboratory network including analytical devices for performing in-vitro diagnosis and a gateway is proposed. The network is configured to send a data package request including information regarding the analytical devices from the gateway to a remote service platform, receive from the remote service platform information regarding available data packages, determine a selection of the available data packages to be downloaded from the remote service platform specific to the analytical devices in the network, request the selection of the available data packages from the remote service platform, download the requested selection of the available data packages from the remote service platform, and provide the requested selection of the available data packages to the analytical devices.

公开(公告)号：USD900147S1

公开(公告)日：2020-10-27

申请号：US29676477

申请日：2019-01-11

Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.

Designer： Luc St. Arnaud ,  Sandra Roth ,  Olgu Guenal

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20200292483A9

公开(公告)日：2020-09-17

申请号：US16441282

申请日：2019-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Marquant ,  Samuel Evgin ,  Melanie Klein

IPC: G01N27/327

Abstract: A method for determining a concentration of at least one analyte in bodily fluid, comprising: a signal generation step, wherein an excitation voltage signal is generated by a signal generator, wherein the excitation voltage signal comprises a poly frequent alternating current (AC) voltage and a direct current (DC) voltage profile, wherein the poly frequent AC voltage comprises at least two frequencies; a signal application step, wherein the excitation voltage signal is applied to at least two measurement electrodes; a measurement step, wherein a response is measured by using the measurement electrodes; an evaluation step, wherein an AC current response for each frequency and a DC current response are evaluated from the response; a determination step, wherein the concentration of the analyte is determined from the DC current response and from one or both of the phase and impedance information by using at least one predetermined relationship.

公开(公告)号：US10775355B2

公开(公告)日：2020-09-15

申请号：US16009434

申请日：2018-06-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Tobias Franz ,  Uwe Kobold ,  Peter Kupser ,  Roland Thiele

IPC: G01N30/88 ,  G01N30/06 ,  G01N30/08 ,  G01N30/24 ,  G01N30/46 ,  G01N30/72 ,  G01N35/00 ,  B01D15/18 ,  G01N30/60 ,  G01N1/40 ,  G01N30/02

Abstract: A clinical diagnostic system is presented and comprises a sample preparation station for automatically preparing samples comprising analytes of interest, a liquid chromatography (LC) separation station comprising a plurality of LC channels and a sample preparation/LC interface for inputting prepared samples into the LC channels. The system further comprises a controller to assign samples to pre-defined sample preparation workflows each comprising a pre-defined sequence of sample preparation steps and requiring a pre-defined time for completion depending on the analytes. The controller further assigns an LC channel for each prepared sample depending on the analytes and plans an LC channel input sequence for inputting the prepared samples that allows analytes from different LC channels to elute in a non-overlapping LC eluate output sequence based on expected elution times. The controller further sets and initiates a start sequence that generates a prepared sample output sequence that matches the LC channel input sequence.

公开(公告)号：US20200271683A1

公开(公告)日：2020-08-27

申请号：US16646206

申请日：2018-11-28

Applicant: HITACHI HIGH-TECHNOLOGIES CORPORATION ,  ROCHE DIAGNOSTICS OPERATIONS, INC. ,  F. HOFFMANN-LA ROCHE AG

Inventor： Chikook HA ,  Mohamed ABOUELSOUD

IPC: G01N35/10 ,  G01N35/00 ,  G01N35/04

Abstract: In an automatic analyzer in which required maintenance can be executed efficiently, without omission, an operation control unit controls operations of an analysis module (ISE, AU1, AU2) including a sample vessel transport mechanism, a reagent vessel transport mechanism, a reaction vessel transport mechanism, a sample dispensing mechanism, and a reagent dispensing mechanism, and of a display unit, and analyzes a sample accommodated in a reaction vessel. The operation control unit stores a validity period for each maintenance item of the analysis module (ISE, AU1, AU2) and an execution time for each maintenance item in a memory, displays an execution time together with an identification representation of execution priority level based on the expiration dates on the display unit, rearranges the display order of the maintenance items on the basis of the execution priority level, in accordance with an operator's instruction inputted through an operation input portion.

公开(公告)号：US20200271670A1

公开(公告)日：2020-08-27

申请号：US16868644

申请日：2020-05-07

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk Block ,  Hans-Peter Brunner ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Thomas Dieterle ,  Cheryl Mitchell ,  Johan Ubby ,  Sandra Sanders-van Wijk

IPC: G01N33/68 ,  G01N33/62 ,  G01N33/66 ,  G01N33/70 ,  G01N33/72 ,  G01N33/84

Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

公开(公告)号：US20200246476A1

公开(公告)日：2020-08-06

申请号：US16852931

申请日：2020-04-20

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Harmut Duefel ,  Uwe Kobold ,  Andreas Leinenbach

IPC: A61K47/68 ,  G01N33/68

Abstract: The present disclosure is directed at an antibody conjugate having an antibody and a tag, wherein one or more element(s) present in the antibody exhibit an isotope ratio which differs from the naturally occurring isotope ratio of the one or more element(s), wherein the amount of the isotope which is less-common in nature, is increased to at least 4% of the atoms of the respective element in the antibody, as well as uses thereof.

公开(公告)号：US10722650B2

公开(公告)日：2020-07-28

申请号：US14229016

申请日：2014-03-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： David L. Duke ,  Abhishek S. Soni

IPC: A61M5/172 ,  A61M5/142 ,  G06F19/00 ,  G16H50/30 ,  A61B5/145 ,  A61B5/00

Abstract: The present disclosure relates to a system and method for determining a basal rate adjustment based on risk associated with a glucose state of a person with diabetes. A method may include detecting a glucose state of the person based on a received glucose measurement signal and determining a current risk metric associated with the detected glucose state. The method may include identifying a reference glucose state and a reference risk metric associated with the reference glucose state, and calculating an adjustment to a basal rate of a therapy delivery device based on the current risk metric associated with the detected glucose state and the reference risk metric associated with the reference glucose level.

公开(公告)号：US20200225184A1

公开(公告)日：2020-07-16

申请号：US16829788

申请日：2020-03-25

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Michael Lambertson ,  Klaus Bauer-Espindola ,  Samuel Evgin ,  Carina Horn ,  Michael Marquant

IPC: G01N27/327

Abstract: A method for determining an information on an equivalent series resistance is disclosed and comprises: generating at least one excitation voltage signal and applying the excitation voltage to at least two measurement electrodes; measuring a response signal; determining a signal flank from the response signal and determining an ohmic signal portion from one or both of shape and height of the signal flank; and determining the information on the equivalent series resistance from the ohmic signal portion.